Please wait while we take you to your selected region.
PNC-27 is a research peptide studied for potential anti-cancer activity. In laboratory studies, it appears to selectively target cancer cells by binding to HDM-2 proteins on their membranes, leading to membrane disruption and cell death.
In experiments on leukemia cell lines, it showed cytotoxic effects against cancer cells while sparing normal control cells. Its proposed mechanism involves inducing necrosis through pore formation in tumor cell membranes, independent of p53.
PNC proteins were developed in 2000 by Drs. Matthew Pincus and Joseph Michl at SUNY Downstate Medical Center. Originally designed for HIV research, PNC-27 attracted attention for its ability to target cancer cells while sparing normal cells.
PNC-27 works by binding to HDM-2, a protein found in the membranes of many cancer cells. This interaction allows the peptide to form pores or holes in the cancer cell membrane. The resulting membrane damage, known as membranolysis, causes the cancer cell to die.
Research published in 2010 reported that PNC-27 forms oligomeric pores in tumor-cell membranes but not in normal cells. Researchers suggested that the unusual presence of MDM2 in cancer cell membranes may help explain the peptide's selectivity. However, further clinical trials are needed to determine its safety and effectiveness in humans.
PNC-27 has also been discussed in scientific presentations, including a TED Talk by Dr. Ehsan Sarafraz-Yazdi.
Animal studies have reported changes during treatment with PNC-27, including reduced pain, flu-like symptoms, and changes in certain blood markers. These effects may be related to the body's response to damaged tumor cells. Tumor breakdown and changes in energy levels have also been observed in some experimental models.
Reported side effects in animal studies include skin and nasal inflammation, watery eyes, dry skin, increased blood pressure, headaches, back pain, nosebleeds, rectal bleeding, changes in taste, and increased protein in the urine. These findings come from experimental research and may not predict effects in humans.
Studies have suggested that the p53 region of PNC-27 matches the part of p53 that binds to HDM-2. This may allow the peptide to recognize HDM-2 in cancer-cell membranes. Normal cells generally lack this membrane-associated marker, which may explain the proposed selectivity of PNC-27.
Additional experiments showed that normal cells became vulnerable to PNC-27 when HDM-2 was introduced into their membranes. Research also found that the complete peptide, rather than separate fragments, is responsible for forming pores in cancer-cell membranes while nearby normal cells remain viable.
In a 2006 animal study, PNC-28, a related peptide and precursor to PNC-27, slowed or stopped the growth of pancreatic tumors. The peptide caused necrosis in several tumor-cell lines but had little effect on normal cells. Tumor growth remained limited during treatment and for a period afterward, although some regrowth was observed.
When treatment was started after tumors had developed at a distant site, tumor size decreased before slowly returning. Researchers suggested that the peptide may have potential as a cancer treatment, particularly when applied directly to tumors. These findings remain experimental.